Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
revita
- Development stage
- Unknown
- Lead developer
- Tides Medical
- Administration
- Topical
01
Overview
Revita is a dehydrated human amnion-chorion membrane (dHACM) allograft developed by **Tides Medical**. It is uniquely available in two primary multi-layer configurations: **Amnion-Intermediate-Chorion (AIC)** and **Amnion-Chorion-Amnion (ACA)**. These grafts are derived from the human placenta and processed to preserve the natural extracellular matrix (ECM), growth factors, and cytokines essential for tissue regeneration. Revita acts as a biological scaffold that promotes cellular migration, proliferation, and angiogenesis while providing a protective barrier and reducing inflammation. It is primarily indicated for the treatment of chronic wounds, such as **diabetic foot ulcers (DFU)** and **venous leg ulcers (VLU)**, where it serves to accelerate the healing process in patients who have failed standard wound care therapies.
- Brand names
- Revita
- Other names
- Amnion-Intermediate-Chorion + Amnion-Chorion-AmnionAmnion-Intermediate-ChorionAmnion-Chorion-AmnionAICACAdehydrated human amnion-chorion membranedHACM
02
Targets
PDGFR (PDGFR family)EGFR (Epidermal growth factor receptor)VEGFR (VEGFR family)TGFBR (TGF-beta receptor)MET (Mesenchymal-epithelial transition factor receptor)FGFR (FGFR family)
Beyond the preview
Go deeper on revita.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on revita.